Podcasts about diffuse

Jannell and Keith Royer's daughter McKenna was experiencing headaches before her Diffuse Midline Glioma diagnosis in August of 2023. This Pediatric Brain Cancer behaves in a similar manner to DIPG, leaving little room for a lifespan which is normally expected to be 9-12 months.  McKenna did not even make it that far, passing away on February 26th of 2024, 6 months after being diagnosed. Jannell and Keith will talk about how McKenna felt surprisingly well during almost all of her battle, until 8 days before her passing when she suddenly went downhill health wise. Jannell and Keith will also about their Brave Like McKenna Foundation and their advocacy work for the cause of Pediatric Cancer.

In this episode, Dr. Daniel Binus and Jonathan Edens show how to face anxiety and rewire your brain using the DARE method—Diffuse, Allow, Run Toward, Engage—plus the “guard dog” amygdala analogy, graded exposure, and practical tools to channel adrenaline and build resilience.—

Surely, a beautiful old house sold at a bargain must have a sinister history.  One new homeowner is about to find out. Genre: Horror, Mystery   Excerpt: “If afterlife spirits are real, they're real whether I believe in them or not.” I shrugged. “And if they're real, I'd rather not stir them up.” “So…she felt something?”  “She said the place had a weird energy.”  “What does that mean?” I shook my head. “Frustrated….”   What story or stories am I revisiting in this episode?Each Season 8 episode is a standalone story, but it's connected to or inspired by a previous story through a character, a place, an object, a concept, a continuation of events (ahem, sequel), and so on. This story is not the first one I've written about houses with links to the otherworldly (or about potentially reckless bargains with forces that one does not understand). It's predecessor is “Mausefalle Manor.”   MY FIRST BOOK (yay)Ever wonder how I've gotten all these hundreds of stories written?  I have a method. And I talk all about it in my book called Fictioneer's Field Guide: A Game Plan for Writing Short Stories. It's now available from Amazon as an eBook, paperback, and hardcover. You can also get there from my Store page: STORYFEATHER STORE   The Store page also has sign-up forms for my two email newsletters: Storyfeather Gazette (if you'd like to keep up with the fiction I create) Fictioneer's Field Guide (if you'd like writing tips and guidance from me) Choose what you want. (Either way, you're choosing high jinks.)   MERCH!Interested in merch, like mugs and notebooks, featuring my artwork? Please visit my Store page for info on where you can buy: STORYFEATHER STORE   CREDITSStory: “The Infernal Bargain House” Copyright © 2021 by Nila L. Patel Narration, Episode Art, Editing, and Production:  Nila L. Patel   Music: “A dead heart” by NICHOLAS JEUDY (Intro & Outro) “Abstract Vision #5” by ANDREW SITKOV (Outro)   Music by NICHOLAS JEUDY “At night” “Hunter's moon” “Evidence” “Dedale” “Experiment 3” “A dead heart” “Whispers” “Sacrifice” “Ashes” “I'm sorry” “Sins and sinners” “Hidden in the dark” “The death of love”   All these tracks are part of a music and sound effects bundles I purchased from Humble Bundle and sourced from GameDev Market.   Music by Nicholas Jeudy and Andrew Sitkov is licensed from GameDev Market Sound effects from AudioJungle, GameDevMarket, and Soundly (through Hindenburg) Changes made to the musical tracks? Just cropping of some to align with my narration.   Find more music by Nicholas Jeudy and Andrew Sitkov at gamedevmarket.net Find more stories by Nila at storyfeather.com   Episode Art Description: Digital drawing. An oak tree at center whose six visible main branches spread in all directions, some dragging on the ground, some reaching upward, some reaching outward.  Diffuse patches of green in the background suggest leaves sprouting from the thinner branches.  A thin dark haze lays along the ground. A vaguely humanoid shadow floats beside the tree. The rectangular image is made square with borders at top and bottom with blurred extensions of the main image. Watermark of Storyfeather along upper main branch at right.

Quelles recherches, quelles découvertes ont retenu l'attention de nos consœurs et confrères de la presse scientifique ce mois-ci ? Avec Vincent Nouyrigat , Epsiloon : Grandeur et décadence du paresseux géant Franck Daninos, Sciences et Avenir : Seuls ? À la recherche de la vie extraterrestre Philippe Hénarejos, Ciel & Espace :  2023 : et si un astéroïde frappait la lune ? François Lassagne, Pour la Science : Ce que notre santé doit à la vie sociale des mitochondries Elsa Couderc, The Conversation : Comment commence un cancer ? Musiques diffusées  pendant l'émission - Grand Corps Malade – Ensemble - Clara Luciani - La grenade - Calvin Harris, Rag'n'bone Man – Giant - Luedji Luna, Seu Jorge – Apocalipse (Playlist RFI) - Lykke Li - Possibility.

Quelles recherches, quelles découvertes ont retenu l'attention de nos consœurs et confrères de la presse scientifique ce mois-ci ? Avec Vincent Nouyrigat , Epsiloon : Grandeur et décadence du paresseux géant Franck Daninos, Sciences et Avenir : Seuls ? À la recherche de la vie extraterrestre Philippe Hénarejos, Ciel & Espace :  2023 : et si un astéroïde frappait la lune ? François Lassagne, Pour la Science : Ce que notre santé doit à la vie sociale des mitochondries Elsa Couderc, The Conversation : Comment commence un cancer ? Musiques diffusées  pendant l'émission - Grand Corps Malade – Ensemble - Clara Luciani - La grenade - Calvin Harris, Rag'n'bone Man – Giant - Luedji Luna, Seu Jorge – Apocalipse (Playlist RFI) - Lykke Li - Possibility.

The 94 WIP Morning Show reacts to Nick Sirianni being on the show, mainly about his poise in answering the AJ Brown questions. Joe DeCamara thinks Sirianni has improved at how he handles tough questions and did a good job trying to diffuse the situation.

Are you sidestepping the biggest pitfalls on the path to financial freedom and a happy life? In this candid episode, we get real about the three most detrimental mistakes that can derail your financial dreams. We're diving deep into why holding onto debt is a trap society has normalized, and how to break free. We also tackle the critical importance of saving for the future, sharing a clear roadmap to build your retirement savings from your first match dollar to maxing out your accounts. Tune in now to hear the last mistake people make that turns out to be the biggest of them all. This episode is your wake-up call to build a life you truly love, together.       Our website: www.forbetterandworth.com Get Ericka's book, Naked and Unashamed: 10 Money Conversations Every Couple Must Have Check out our local TV spotlight Connect with us: Instagram: @forbetterandworth YouTube: @forbetterandworth Ericka: @erickayoungofficial Chris: @1cbyoung  

In this week's episode we'll learn about persistent changes in immune profiles in patients who have had diffuse large B-cell lymphoma, or DLBCL, and other cancers; that plasminogen activation and plasmin activity do not appear to play a role in routine physiological prevention of venous thromboembolism, or VTE; and about a novel mechanism that makes hematological malignancies carrying epigenetic mutations susceptible to PARP inhibitors.Featured Articles:Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatmentPlasminogen activation and plasmin activity are not required to prevent venous thrombosis/thromboembolismTransposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer

What was thought to be a stomach ailment for Meryl Summers 1st grade daughter Adelia became much more than that in February of 2023 when she was diagnosed with the Pediatric Brain Cancer Diffuse Midline Glioma. Adelia was called the Wonder Girl for so many reasons during her 15 month battle with this disease which very sadly ended with her passing on May 30th of 2024. Since that time, Meryl has become a fierce advocate for the cause of Pediatric Brain Cancer and has testified in the Massachusetts State House for a bill which recognizes the cause of Pediatric Cancer be passed and signed into law as soon as possible. 

Tous les matins, 8h50 sur Chérie FM, Alex et Tiffany l'équipe du Réveil Chérie vont chacun vous donner une info ! Une seule est vraie ! L'autre est complètement fausse !" A vous de trouver qui dit vrai !

Conflict tends to arise due to poor choices and a lack of emotional intelligence. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In today's episode, supported by Chimerix, we spoke with Patrick Y. Wen, MD, about the FDA approval of dordaviprone (Modeyso) for the treatment of adult and pediatric patients at least 1 year of age with H3K27M-mutated diffuse midline glioma who have progressive disease following prior therapy. Dr Wen is the director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute; as well as a professor of neurology at Harvard Medical School in Boston, Massachusetts. In our conversation, Dr Wen discussed the significance of this accelerated approval across patient age groups, key efficacy and safety data that supported this approval, and the importance of biomarker testing in patients with glioma. He also highlighted potential next steps for expanding the investigation of dordaviprone in patients with glioma and emphasized the ways that multidisciplinary collaboration can provide patients with personalized, optimized care. 

Quelles recherches, quelles découvertes ont retenu l'attention de nos consœurs et confrères de la presse scientifique ce mois-ci ? Avec  Louane Velten, Epsiloon : Face à la douleur Mathieu Nowak, Sciences et avenir : Alzheimer, l'espoir est relancé Philippe Henarejos, Ciel & espace : Voie lactée, l'énigme des supernovas manquantes  François Lassagne, Pour la science : Géométrie aléatoire, à la recherche de nouvelles formes et leurs de vibrations Benoît Tonson, The Conversation : Ce que les pleurs de bébés nous disent vraiment Musiques diffusées pendant l'émission Prince - Free (Acoustic Version) (Playlist RFI) Gaetan Roussel – Hope Johnny Cash – Hurt Zap Mama - Zap Bébés Oasis - Champagne Supernova

Quelles recherches, quelles découvertes ont retenu l'attention de nos consœurs et confrères de la presse scientifique ce mois-ci ? Avec  Louane Velten, Epsiloon : Face à la douleur Mathieu Nowak, Sciences et avenir : Alzheimer, l'espoir est relancé Philippe Henarejos, Ciel & espace : Voie lactée, l'énigme des supernovas manquantes  François Lassagne, Pour la science : Géométrie aléatoire, à la recherche de nouvelles formes et leurs de vibrations Benoît Tonson, The Conversation : Ce que les pleurs de bébés nous disent vraiment Musiques diffusées pendant l'émission Prince - Free (Acoustic Version) (Playlist RFI) Gaetan Roussel – Hope Johnny Cash – Hurt Zap Mama - Zap Bébés Oasis - Champagne Supernova

Phil a gouté à sa propre médecine!

In this episode of Built for the Edge, Kehla drops a tool so powerful it will completely rewire how you communicate—with your clients, your partner, your kids, and even yourself. This isn't fluffy mindset talk or toxic positivity. It's a trifecta process that cuts straight to the root of conflict, dissolves misunderstandings in seconds, and builds intimacy and trust in every relationship. For the first time in six years, Kehla is bringing back her most-shared coaching framework—the one she's used for over a decade with paying clients to help them self-coach, hold space without bypassing, and take radical ownership in their business and life. If you're tired of surface-level “just be compassionate” advice and want a concrete method to listen deeply, validate others without people-pleasing, and stay regulated even in heated conversations… this is your episode.

Welcome to this episode of The Oncology Brothers! Drs. Rahul and Rohit Gosain dived into the complexities of relapsed refractory diffuse large B-cell lymphoma (DLBCL) with their new series focused on challenging real-life cases. In this episode, we are joined by esteemed guests Dr. Carla Casulo from Wilmot Cancer Center and Dr. Tara Graff from Mission Cancer and Blood Center. Together, we explored the current standard of care, including R-CHOP and the role of bi-specific antibodies like epcoritamab and glofitimab. Key topics covered included: • When to use bi-specific antibodies and how to manage side effects • The importance of MRD monitoring in treatment decisions • Insights on patient management in community oncology settings • The evolving landscape of treatment options for DLBCL, including CAR-T therapy and clinical trials We also discuss practical considerations for community oncologists, including the management of cytokine release syndrome (CRS) and the role of immunoglobulin therapy in patients with low IgG levels. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable insights and expert opinions. YouTube: https://youtu.be/05ieIyAIx_8 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and share your thoughts in the comments! Let us know if there are specific scenarios you'd like us to cover in future episodes.

Welcome to the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain dive deep into the world of diffuse large B-cell lymphoma (DLBCL), one of the most aggressive yet potentially curable lymphomas. We are joined by Dr. John Leonard, a renowned lymphoma expert from NYU Langone Cancer Center, who shares his insights on the latest data and evolving treatment landscape for DLBCL. Episode Highlights: •⁠  ⁠Understanding the initial workup for DLBCL, including the role of PET-CT and bone marrow biopsies. •⁠  ⁠The use of RCHOP and the emerging Pola-R-CHP regimen in Stage 1 and Stage 2 settings. •⁠  ⁠Discussion on the treatment options for Stage 3 and Stage 4 disease, including the impact of polatuzumab. •⁠  ⁠Insights into managing relapsed/refractory disease and the role of CAR-T therapy. •⁠  ⁠The potential shift towards outpatient CAR-T treatments and the nuances between different CAR-T options. •⁠  ⁠Exploring bispecific antibodies and their applications in treatment sequencing. YouTube: https://youtu.be/raGkPnUs9XM Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us as we unpack the complexities of DLBCL treatment and share valuable clinical pearls for community settings. Don't forget to subscribe for more episodes on challenging cases and the latest in oncology!

Why does criticism from one person cut deep, while the same words from another roll right off your back? For highly sensitive people, criticism can feel like a direct assault on the self. But what if the sting of those words isn't just about what's said—or who says it—but something deeper inside you? This episode unpacks the emotional patterns that keep you trapped in pain and shows how a shift in perception can set you free. Understand why the same criticism feels devastating in one moment and harmless in another. Learn how your internal judge plays a critical role in how deeply criticism impacts you. Discover how to use a simple but profound inner work process to sidestep emotional shutdown and build resilience from within.   If you're ready to turn criticism into a path to self-liberation and inner peace, press play and begin your transformation now.   Todd Smith, founder of True Inner Freedom Dreaming of a stress-free, balanced life? Visit trueinnerfreedom.com and complete the HSP Stress Survey. Gain clarity on your stress triggers and enjoy a free 15-minute Inner Freedom Call designed to guide you toward lasting inner peace and fulfillment. Are you a highly sensitive person (HSP) or someone who identifies as hypersensitive or neurodivergent? This podcast is dedicated to helping highly sensitive people (HSPs) navigate overwhelm and stress by using The Work of Byron Katie—a powerful method for questioning stressful thoughts and finding true inner freedom. We dive deep into stress management strategies, coping with stress, and stress relief methods specifically tailored for HSPs. Learn how to manage emotions, especially negative ones, and explore effective stress reduction techniques that go beyond the surface to address the root causes of anxiety and pressure. Whether you're interested in learning how to lower stress, handle stress and pressure, or reduce stress through practical techniques, we provide insights and support based on The Work of Byron Katie. Discover how this transformative approach can help you decrease stress, find inner peace, and create balance in your life. Join us to learn about various coping strategies for stress, all designed to support HSPs in their journey toward emotional well-being.

durée : 00:08:36 - L'invité de 7h50 du week-end - par : Kevin Dufreche - L'actrice Zita Hanrot était l'invitée de France Inter ce dimanche pour présenter le film "Aux jours qui viennent", réalisé par Nathalie Najem et en salles le 23 juillet. - invités : Zita Hanrot - Zita Hanrot : Comédienne Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Quelles recherches, quelles découvertes ont retenu l'attention de nos consœurs et confrères de la presse scientifique ce mois-ci ?   Avec : Muriel Valin, Epsiloon : Laissons-nous rêvasser Franck Daninos, Sciences et Avenir : Planète 9 : après la théorie, l'heure de l'observation  Philippe Hénarejos, Ciel & Espace : Mars, portrait d'une planète habitable  François Lassagne, Pour la Science : À la recherche des planètes manquantes  Elsa Couderc, The Conversation : Détecter les contenus pédocriminels en ligne : quelles options techniques ? Quels risques pour la vie privée ? Musiques diffusées pendant l'émission : - Piers Faccini, Ballaké Sissoko - One Half of a Dream [Playlist RFI] - DjeuhDjoah, Lieutenant Nicholson – Planète - Pierre Kwenders, Pierre Lapointe, NegoO - Clair De Lune [Playlist RFI] - Tiken Jah Fakoly - Arriver à rêver - Polo and Pan - Attrape rêve.

Quelles recherches, quelles découvertes ont retenu l'attention de nos consœurs et confrères de la presse scientifique ce mois-ci ?   Avec : Muriel Valin, Epsiloon : Laissons-nous rêvasser Franck Daninos, Sciences et Avenir : Planète 9 : après la théorie, l'heure de l'observation  Philippe Hénarejos, Ciel & Espace : Mars, portrait d'une planète habitable  François Lassagne, Pour la Science : À la recherche des planètes manquantes  Elsa Couderc, The Conversation : Détecter les contenus pédocriminels en ligne : quelles options techniques ? Quels risques pour la vie privée ? Musiques diffusées pendant l'émission : - Piers Faccini, Ballaké Sissoko - One Half of a Dream [Playlist RFI] - DjeuhDjoah, Lieutenant Nicholson – Planète - Pierre Kwenders, Pierre Lapointe, NegoO - Clair De Lune [Playlist RFI] - Tiken Jah Fakoly - Arriver à rêver - Polo and Pan - Attrape rêve.

Merriam-Webster's Word of the Day for July 1, 2025 is: verbose • ver-BOHSS • adjective Someone described as verbose tends to use many words to convey their point. Verbose can also describe something, such as a speech, that contains more words than necessary. // The article documenting their meeting presented an odd exchange between a verbose questioner and a laconic interviewee. See the entry > Examples: "The dense, verbose text—over which some actors stumbled, understandably, on opening night—created a dizzying journey through a war between gods and mortals fought across time and place." — Rosa Cartagena, The Philadelphia Daily News, 19 Feb. 2025 Did you know? There's no shortage of words to describe wordiness in English. Diffuse, long-winded, prolix, redundant, windy, repetitive, rambling, and circumlocutory are some that come to mind. Want to express the opposite idea? Try succinct, concise, brief, short, summary, terse, compact, or compendious. Verbose, which falls solidly into the first camp of words, comes from the Latin adjective verbōsus, from verbum, meaning "word." Other descendants of verbum include verb, adverb, proverb, verbal, and verbicide ("the deliberate distortion of the sense of a word").

“No! I don't want to!” How many times have dads heard something like this? Is it defiance, or something else? Kids talking back is part of growing up. Dads need to know how to react when their children get mouthy. In this episode of the All Pro Dad Podcast, host Ted Lowe is joined by BJ Foster and Bobby Lewis to talk about keeping our cool when this happens in our homes.Why This MattersThere are different kinds of “talking back,” and handling them all the same could lead to friction in your relationship with your kids. Key TakeawaysTalking back, or being “mouthy,” is developmentally normal. Recognize that there are always reasons kids talk back. Practical Tools for DadsWhen your kids get mouthy, try these techniques to better understand their behavior:1. Stay calm. 2. Acknowledge their feelings. 3. Treat them with respect. 4. Remind them of the parent/child dynamic5. Focus on the message. Important Episode Timestamps00:00 – 00:55 | Introduction & Big Question of the Week00:55 – 03:13 | Personal Stories: Were You a Mouthy Kid?03:13 – 05:10 | Why Back Talk Pushes Our Buttons05:10 – 07:07 | Defiant vs. Dismissive: What Kind of Back Talk Is It?07:07 – 09:50 | Reacting vs. Responding: Fear-Based Parenting Doesn't Last09:50 – 13:36 | The Power of Curiosity: What's Really Going On?13:36 – 15:15 | The Role of Imitation in Behavior15:15 – 17:58 | Practical Tools to Diffuse the Moment17:58 – 22:00 | Teach, Don't Just Stop the Behavior22:00 – 28:00 | Pro Move of the Week:  Remember, mouthy kids are normal kids. They just need guidance. Sponsor:The All Pro Dad Podcast is proudly brought to you by Family First, a nonprofit dedicated to equipping parents with resources to strengthen their families. Learn more at FamilyFirst.net.We love feedback, but can't reply without your email address. Message us your thoughts and contact info!Connect with Us: Ted Lowe on LinkedIn Bobby Lewis on LinkedIn BJ Foster on LinkedIn Subscribe on Apple Podcasts Get All Pro Dad merch! EXTRAS: Follow us: Instagram | Facebook | X (Twitter)Join 200,000+ other dads by subscribing to the All Pro Dad Play of the Day. Get daily fatherhood ideas, insight, and inspiration straight to your inbox.This episode's blog can also be viewed here on AllProDad.com. Like the All Pro Dad gear and mugs? Get your own in the All Pro Dad store.Get great content for moms at iMOM.com

World War II bombs were defused in Cologne, Germany, which has inspired us to explore the science of diffusion and defusing!First, we hear how new, artificially intelligent video generators are modelled on diffusion. We also hear about the health impacts of home aroma diffusers and candles. We're joined by conflict-mediator Gabrielle Rifkind of the Oxford Process, to discuss the psychological stakes behind defusing conflict in wars and at home.We also taste-test the difference between raw and cooked broccoli, learn about in-insect synthesis, and explore an anechoic chamber. All that, plus many more Unexpected Elements. Presenter: Caroline Steel, with Tristan Ahtone and Edd Gent Producer: Imaan Moin, with Alice Lipscombe-Southwell, Minnie Harrop and Debbie Kilbride

Which patients with IDH-mutant glioma should receive an isocitrate dehydrogenase (IDH) inhibitor? A top neurosurgeon weighs in. Credit available for this activity expires: 6/9/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002598?ecd=bdc_podcast_libsyn_mscpedu

Klinisch Relevant ist Dein Wissenspartner für das Gesundheitswesen. Drei mal pro Woche, nämlich dienstags, donnerstags und samstags, versorgen wir Dich mit unserem Podcast und liefern Dir Fachwissen für Deine klinische Praxis. Weitere Infos findest Du unter https://klinisch-relevant.de

Dr. Evan Noch interviews Dr. Marion Mateos about her and her team's recent manuscript entitled: "Germline analysis of an international cohort of pediatric diffuse midline glioma patients", published online in Neuro-Oncology in March 2025.

Quelles recherches, quelles découvertes ont retenu l'attention de nos consœurs et confrères de la presse scientifique ce mois-ci ?  Avec : Muriel Valin, Epsiloon : cartographie des fonds marins Mathieu Nowak, Sciences et Avenir : intestins, comprendre et combattre les maux de ventre David Fossé, Ciel & Espace : le succès historique de Camille Flammarion avec son «Astronomie populaire». François Lassagne, Pour la Science : autisme, un héritage de Néandertal ?  Thomas Delozier Science&Vie : requin blanc, ce que le monde doit aux superprédateurs Benoît Tonson, The Conversation : L'empathie n'est pas le propre de l'humain : ces singes utilisent des signaux vocaux pour se réconforterMusiques Diffusées pendant l'émission :- Big Thief - Shark smile- Tekemat, Mariaa Siga, Guiz - Comme il Est [Playlist RFI]- Miira - Où vont les larmes [Playlist RFI]- Volodia, Davojah - Regarde le ciel.

Quelles recherches, quelles découvertes ont retenu l'attention de nos consœurs et confrères de la presse scientifique ce mois-ci ?  Avec : Muriel Valin, Epsiloon : cartographie des fonds marins Mathieu Nowak, Sciences et Avenir : intestins, comprendre et combattre les maux de ventre David Fossé, Ciel & Espace : le succès historique de Camille Flammarion avec son «Astronomie populaire». François Lassagne, Pour la Science : autisme, un héritage de Néandertal ?  Thomas Delozier Science&Vie : requin blanc, ce que le monde doit aux superprédateurs Benoît Tonson, The Conversation : L'empathie n'est pas le propre de l'humain : ces singes utilisent des signaux vocaux pour se réconforterMusiques Diffusées pendant l'émission :- Big Thief - Shark smile- Tekemat, Mariaa Siga, Guiz - Comme il Est [Playlist RFI]- Miira - Où vont les larmes [Playlist RFI]- Volodia, Davojah - Regarde le ciel.

Des astronomes slovaques viennent de calculer l'impact sur les observatoires astronomiques de la lumière diffusée par les minuscules débris spatiaux en orbite basse dont la quantité est en croissance exponentielle du fait du déploiement des mégaconstellations de satellites. L'étude est publiée dans Monthly Notices of the Royal Astronomical Society Letters. Source Low Earth Orbit satellite fragmentation rates are critically disrupting the natural night sky backgroundM Kocifaj et al.Monthly Notices of the Royal Astronomical Society: Letters, Volume 541, (22 may 2025)https://doi.org/10.1093/mnrasl/slaf052 Illustration Carte en coordonnées polaires de la luminosité diffuse en 2035 pour les observatoires Vera Rubin (haut) et ZTF (bas). Les valeurs sont données pour le haut de l'atmosphère (gauche) et au sol (droite).

In this week's episode we'll learn about how frequent blood donation affects clonal hematopoiesis in older, male blood donors; the effect of immune microenvironment on response to bispecific antibodies in diffuse large B-cell lymphoma; and the feasibility of adding blinatumomab to early consolidation therapy in CD19-positive Ph-negative B-cell acute lymphoblastic lymphoma.Featured ArticlesClonal Hematopoiesis Landscape in Frequent Blood DonorsIntegrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody responseUpfront Blinatumomab Improves MRD Clearance and Outcome in Adult Ph-negative B-lineage ALL: The GIMEMA LAL2317 Phase 2 Study

Dr. Iyad Alnahhas interviews Drs. Cynthia Hawkins and Arun Vadivel about their recent manuscript entitled: "The proteomic landscape of diffuse midline glioma highlights the therapeutic potential of non-histone protein methyltransferases", published online in Neuro-Oncology in February 2025.   More Information

- Overview of Diffuse Large B-Cell Lymphoma - Staging & Grading - Current Standard of Care - Treatment Options for Resistant Disease - New & Emerging Treatment Approaches - The Role of Clinical Trials - How Research Contributes to Treatment Choices - Tips to Manage Treatment Side Effects, Symptoms, Discomfort & Pain - The Increasing Role of Telehealth/Telemedicine Appointments - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Questions to Ask Our Panel of Experts

Quelles recherches, quelles découvertes ont retenu l'attention de nos consœurs et confrères de la presse scientifique ce mois-ci ? Avec : Muriel Valin, Epsiloon : l'IA fait revivre les génies  Arnaud Devillars, Sciences et Avenir : IA contre IA ou comment traquer les «deepfakes» ? David Fossé, Ciel & Espace : matière noire François Lassagne, Pour la Science : matière noire, les impasses, les nouvelles pistes... Dylan Beiner, Science&Vie : quantique enfin en direct. Musiques Diffusées pendant l'émission :- La Femme - Waiting in the Dark- Imagination - Just An Illusion- MLCD - The tragic tale of a genius- Moliy, Silent Addy, Skillibeng, Shenseea - Shake It To The Max (FLY) [Remix] [Playlist RFI]- Camille, Matthieu Saglio - Ginkgo Biloba [Playlist RFI]

Quelles recherches, quelles découvertes ont retenu l'attention de nos consœurs et confrères de la presse scientifique ce mois-ci ? Avec : Muriel Valin, Epsiloon : l'IA fait revivre les génies  Arnaud Devillars, Sciences et Avenir : IA contre IA ou comment traquer les «deepfakes» ? David Fossé, Ciel & Espace : matière noire François Lassagne, Pour la Science : matière noire, les impasses, les nouvelles pistes... Dylan Beiner, Science&Vie : quantique enfin en direct. Musiques Diffusées pendant l'émission :- La Femme - Waiting in the Dark- Imagination - Just An Illusion- MLCD - The tragic tale of a genius- Moliy, Silent Addy, Skillibeng, Shenseea - Shake It To The Max (FLY) [Remix] [Playlist RFI]- Camille, Matthieu Saglio - Ginkgo Biloba [Playlist RFI]

Dr. Nimish Mohile and Dr. Jaishri Blakeley share the new rapid recommendation update to the therapy for diffuse astrocytic and oligodendroglial tumors in adults guideline. They review the evidence from the INDIGO trial that prompted this update, and how to incorporate the use of vorasidenib into clinical practice. They discuss the importance of molecular testing, particularly for IDH1 or IDH2 mutations and outstanding questions for treatment of patients with oligodendrogliomas and astrocytomas. Read the latest update, “Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update.” Transcript This guideline, clinical tools, and resources are available at http://www.asco.org/neurooncology-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in Journal of Clinical Oncology.   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts.   My name is Brittany Harvey and today I'm interviewing Dr. Jaishri Blakeley from Johns Hopkins University School of Medicine and Dr. Nimish Mohile from the Department of Neurology and Wilmot Cancer Institute at the University of Rochester Medical Center, co-chairs on “Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: American Society of Clinical Oncology-Society for Neuro-Oncology Guideline Rapid Recommendation Update.”  Thank you for being here today, Dr. Blakeley and Dr. Mohile.  Dr. Jaishri Blakeley: Thank you.  Dr. Nimish Mohile: Thank you for having us.  Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Blakeley and Dr. Mohile who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes.   So then, to jump into the content here, Dr. Mohile, could you start us off by describing what prompted this rapid update to the ASCO-SNO therapy for diffuse astrocytic and oligodendroglial tumors in adults guideline, which was previously published in 2021?  Dr. Nimish Mohile: Yeah. So the key reason for this update is the publication of a study in 2023. And this was a study called the INDIGO study that looked at a new class of therapies, something called IDH inhibitors. And in this study with a drug called vorasidenib, changed how we think about the treatment of oligodendrogliomas and astrocytomas, so particularly the grade 2 oligodendrogliomas and grade 2 astrocytomas. Because of the results of that study, we decided that we needed to do an update to inform clinicians about some of these changes and how we might approach these tumors differently today.  Brittany Harvey: Great. I appreciate that background. So then, based off the new data from the INDIGO study, what are the updated and new recommendations from the expert panel?  Dr. Nimish Mohile: So the key findings from the INDIGO study involved people who had grade 2 astrocytomas and grade 2 oligodendrogliomas. And in the setting after surgery, they were treated with vorasidenib, and what they found is that this delayed the time to next intervention. And the key aspect of that is that it delayed when we could start radiation and chemotherapy in these patients.   So what we did in the guidelines is that for both low grade oligodendrogliomas and low grade astrocytomas, we added one additional guideline statement. Our previous guideline in 2021 offered the options for observation or treatment with radiation and chemotherapy. And now in this guideline, we have options for observation, treatment with vorasidenib in those in whom we feel it is safe to defer radiation and chemotherapy, and then treatment with radiation and chemotherapy. So we've added in an additional option here. And the key message of the guideline is really on how, as clinicians, we think about using the vorasidenib and what the ideal setting for using the vorasidenib is.  Brittany Harvey: Excellent. It's great to hear about this new option for patients. So then you were just talking about how we think about who to offer this IDH inhibitor to. So, Dr. Blakeley, what should clinicians know as they implement these new recommendations into practice?  Dr. Jaishri Blakeley: Yes. So, first and foremost, let's go back to 2021, and a key note from those guidelines was the importance of molecular testing. And at that point, the importance of molecular testing, which in large part was focused on IDH1 or IDH2 mutations, was prognostic. We could say there's a difference in an IDH1 mutant astrocytoma and an IDH1 wild type astrocytoma, but we didn't have a specific therapeutic recommendation attached to that, like Dr. Mohile just said. And the big shift here is now we have a specific therapeutic for that population with IDH1 or IDH2 mutant glioma.   So for clinicians, we hope that they've been getting molecular testing on newly diagnosed glioma already, but now there's an additional motivation to do so because it may change your treatment plan in the right circumstance. So since the publication of the phase III INDIGO study that Dr. Mohile mentioned, and the FDA approval of vorasidenib, if you meet the specified criteria in the clinical trial - which the guidelines point out is a little different than what's on the FDA label, so clinicians might want to dig into that a little bit - then there is a treatment option that is new and different than combined chemoradiation or radiation alone or observation.  Brittany Harvey: I appreciate those clarifications there.   So then also, Dr. Blakeley, how does this update impact patients with astrocytic or oligodendroglial tumors?  Dr. Jaishri Blakeley: So first, patients also should know if they have IDH mutant gliomas. And this update only applies to people with IDH1/2 mutant glioma. Perhaps, we're not sure, it might only apply to people who are in the newly or newly-ish diagnosed category because the INDIGO study required that people were within the first five years of their surgical diagnosis and had not had other treatment. So there are a lot of people who have astrocytoma or oligodendroglioma who may or may not know their IDH1/2 status and may have already had another therapy - this update doesn't apply to them. We hope that future research will teach us about that. This update is for people who are newly diagnosed and just starting the journey to figure out the best therapy. It does say that if you do have that IDH1/2 alteration in your tumor, there is a drug therapy that is different from the drug therapies we would offer gliomas that do not have the IDH1/2 mutation.  Brittany Harvey: Absolutely. I think both that emphasis on molecular testing is very important and also thinking about that study inclusion criteria and how it impacts who's eligible for this treatment.   So then finally, Dr. Mohile, what are the outstanding questions about vorasidenib or other interventions for gliomas in adults?  Dr. Nimish Mohile: I think the key question for clinicians is exactly who we're going to use this in. The challenges with inclusion criteria in clinical trials is they don't actually always match what we're seeing in the clinic. And I think it brings up the question of, in low grade oligodendrogliomas which we think of as very slow growing tumors, do we have the option outside of the strict inclusion criteria to use that drug in other settings? I think it brings up the question for some clinicians in some of the higher grade tumors, in the grade 3 tumors, we don't yet have data in that area and our guideline doesn't address that. But I think some will be asking what the clinical activity of vorasidenib is in that setting. There are some suggestions that the IDH inhibitors may impact seizure control, and I think that that's data that we're continuing to wait on.   So I think that there's several outstanding questions there that we will have answers for hopefully in the next several years. I think the big question that we don't have an answer for and that will take a long time to know is whether the addition of vorasidenib in this setting actually improves how long people live. And given how long people with low grade oligodendrogliomas and low grade astrocytomas live today, we probably won't have an answer to that question for more than a decade.  Brittany Harvey: Definitely. We'll look forward to these ongoing developments and eventually longer term data on overall survival on these agents.   So, I want to thank you both so much for your work to rapidly include this information from this new trial. And thank you for your time today, Dr. Blakeley and Dr. Mohile.  Dr. Jaishri Blakeley: Thank you so much.  Dr. Nimish Mohile: Thank you Brittany.  Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/neurooncology-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.    The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. 

In this week's episode we'll learn about the role of interleukin-1 signaling in the bone marrow microenvironment in the development of myelodysplastic syndromes, the immune checkpoint regulator VISTA as a potential target for preventing graft-vs-host disease, and epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma.Featured Articles:IL-1R1 and IL-18 signals regulate mesenchymal stromal cells in an aged murine model of myelodysplastic syndromesTargeting cell-surface VISTA expression on allospecific naïve T cells promotes toleranceEpcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Quelles recherches, quelles découvertes ont retenu l'attention de nos consœurs et confrères de la presse scientifique ce mois-ci ? Avec : Emilie Rauscher, Epsiloon : Il était une fois la vache  Franck Daninos , Sciences et Avenir : Objectif Mars, les défis d'un vol habité David Fossé, Ciel & Espace : hors-série sur les découvreurs de l'Univers Benoit Tonson, The Conversation : Les bonobos font des phrases (presque) comme nous Thomas Delozier, Science&Vie : Editer l'ADN avant la naissanceMusiques Diffusées pendant l'émission : Thomas Fersen – Un coup de queue de vache Dumis9ne, Stepart, 16 Bazz – Intuition (avec 16 Bazz) Jimi Tenor – Is There Love In Outer Space DjeuhDjoah, Lieutenant Nicholson – Danse Divine

Quelles recherches, quelles découvertes ont retenu l'attention de nos consœurs et confrères de la presse scientifique ce mois-ci ? Avec : Emilie Rauscher, Epsiloon : Il était une fois la vache  Franck Daninos , Sciences et Avenir : Objectif Mars, les défis d'un vol habité David Fossé, Ciel & Espace : hors-série sur les découvreurs de l'Univers Benoit Tonson, The Conversation : Les bonobos font des phrases (presque) comme nous Thomas Delozier, Science&Vie : Editer l'ADN avant la naissanceMusiques Diffusées pendant l'émission : Thomas Fersen – Un coup de queue de vache Dumis9ne, Stepart, 16 Bazz – Intuition (avec 16 Bazz) Jimi Tenor – Is There Love In Outer Space DjeuhDjoah, Lieutenant Nicholson – Danse Divine

What a treat to have Dr. Tabatha Barber, author of the best-selling book Fast To Faith, on the podcast. She explained that our bodies function like a chemistry experiment. When we think in a certain way, we produce chemicals that can have positive or negative effects. I don't know about you, but I do find it shocking that the thoughts I think can create chemical messengers in my body that can heal me or harm me. You have so much more power than you realize! We also discussed a topic near and dear to my heart, JOY. Where's your joy? If we put everyone else first, that will steal your happiness. Dr. T. explained that we get caught up in the lie that taking care of ourselves is selfish. She said that she felt God tell her that caring for herself wasn't selfish but SELF PRESERVATION. Dr. Tabatha shared simple tips that can help you to change your mindset and increase your daily joy. Please enjoy part one of this conversation and join us next week when we talk about 20-minute or less dinners, fasting, and her lifelong battle with depression. ______ Young Living Here's the link to my favorite essential oil kit from Young Living! The kit is called Make A Shift, and here are some suggestions on how to use these oils, along with tips on using your new essential oil diffuser (diffuser is also included!) Use the code SHAREYL for 10% off of your first order Put a few drops of Purification essential oil blend on cotton balls and place them in air vents to eliminate odors. Diffuser Lavender essential oil to create a restful environment before bed. Dilute Peppermint essential oil and rub it on your chest for a refreshing breathing experience. Roll Deep Relief Roll-On onto muscles and joints after a workout. Glide Stress Away Roll-On onto your temples for a moment of calm after a challenging day. Diffuse 8–10 drops of essential oils in the FreshStart Diffuser to freshen the air and set the scene for work, play, or rest. Click here to purchase: https://www.youngliving.com/us/en/product/make-a-shift-essential-solutions-kit?enrollerId=4557460&sponsorId=4557460 ______ Air Dr. I've been using the Air Doctor air purifier for almost a year and absolutely love it! I first heard about it from Dr. Mark Hyman, and even though it was a bit of a splurge compared to what I usually spend, I'm so glad I invested. Every time I change the filter and see all the gunk it collects, I smile, knowing it's doing a great job keeping my air clean! And I'm so happy that all that gunk isn't going into my body ;) Click here to purchase: https://airdoctorpro.com/?oid=17&affid=6165 ______ About Dr. Tabitha Barber Dr. Tabatha Barber is a doctor, author, speaker, and devoted Jesus-lover, as well as a proud mom and grandma. Overcoming the challenges of being a high school dropout and teenage mother, she became a triple board-certified physician in obstetrics and gynecology, menopause, and functional medicine. Through her medical practice, podcast, Fast to Faith supplement line, coaching academy, and international best-selling book, Fast to Faith, she empowers women to take charge of their health by addressing gut health, hormone balance, mindset, and spiritual well-being. Connect With Dr. Tabitha Barber Website: https://drtabatha.com/ Instagram: https://www.instagram.com/gutsydrtabatha/# Facebook: https://www.facebook.com/DrTabatha ______ Connect with Deborah Deborah on Instagram: https://www.instagram.com/whydidigetcancer/ Deborah on Facebook: https://www.facebook.com/DebsHealthCoachKitchen Deborah on Twitter: https://twitter.com/ydidigetcancer Deborah on Pinterest: https://in.pinterest.com/whydidigetcancer/ Join Deb's weekly newsletter!  -https://whydidigetcancer.us14.list-manage.com/subscribe?u=1c37affeccf004c8957941069&id=a8572db3c2

In this episode, Dr E and Dr Wells discuss a case of acute low back pain from a fall. That part was easy! With further discussion, the patient also reported chronic leg pain that has been progressively worsening. It was diffuse, felt in bilateral lower legs, and accompanied by unexplained bruising.Untold Physio Stories is sponsored by⁠Comprehend PT⁠- Leave Comprehend PT running in the background or record audio when you have time. The AI based SOAP note generator does the rest! No need for accuracy or exact wording! It's a game changer and will give you more time with your patients! Use code MMT50 to save 50% off your first month. Free trial available at sign up!⁠⁠The Eclectic Approach Network⁠⁠ - Check out Dr. E's all new private, non tracking and ad free network for rehab pros! It's free to join, has chat, feed, and all the features of other social networks without the creeping tracking.Check out ⁠⁠EDGE Mobility System⁠⁠'s Best Sellers - Something for every PT, OT, DC, MT, ATC or Fitness Minded Individual https://edgemobilitysystem.com

In this episode of Mind Shift, Aaron and Erwin McManus reflect on their time in Mexico City, where the Mosaic community has grown from 60 to 225 attendees in a small art gallery space. They celebrate the resilience and teamwork of the community, highlighting how adversity has strengthened their bond. This theme of overcoming conflict and fostering unity extends into a broader discussion on leadership, negotiation, and personal growth.Erwin shares key insights into conflict resolution, emphasizing the importance of diffusing crises without escalating them. He explains how power should not be fought with power, advocating instead for humility and adaptability in leadership. Drawing from his experiences in South Dallas working with drug cartels, he illustrates the value of seeing the world from another person's perspective and finding solutions that benefit all parties involved.The conversation delves into different approaches to leadership, with Aaron and Erwin comparing their psychological assessments and how their personalities shape the way they navigate conflicts. Erwin underscores the necessity of self-awareness and emotional control, warning against letting ego drive decision-making. He shares his rules for conflict resolution—never be the bomb, avoid responding to conflict with aggression, and step away if you cannot present the best version of yourself.The discussion expands to leadership on a global scale, using the Trump-Zelensky interaction as an example of how conflicts could be better managed through strategic humility and gratitude. Erwin explains how simple acts of appreciation can de-escalate tension and shift the dynamic of a conversation. He stresses the importance of intention in leadership, urging leaders to focus on their motivations rather than striving for perfection.As the episode concludes, Aaron and Erwin hint at a multi-part series on conflict resolution, diving deeper into identifying destructive behaviors, navigating difficult situations, and fostering peace. They invite listeners to join the Mind Shiftcommunity for exclusive content and discussions, encouraging engagement with these vital leadership and personal growth lessons.

Quelles recherches, quelles découvertes ont retenu l'attention de nos consœurs et confrères de la presse scientifique ce mois-ci ?   Valérie Greffoz, Epsiloon : La glace noire Mathieu Nowak, Sciences et Avenir : L'Everest Guillaume Langin, Ciel & Espace : Où irons-nous vivre ? Elsa Couderc, The Conversation :Jusqu'où Einstein avait-il raison ?  François Lassagne, Pour la Science : Les nouveaux mondes de l'ARN.Musiques diffusées- Public Service Broadcasting – Everest- Beach House - Space Song- Goodie Mob, Outcast - Black Ice (Sky High)- I Monster – Cells- Piers Faccini, Ballaké Sissoko - If Nothing Is Real [Playlist RFI].

Quelles recherches, quelles découvertes ont retenu l'attention de nos consœurs et confrères de la presse scientifique ce mois-ci ?   Valérie Greffoz, Epsiloon : La glace noire Mathieu Nowak, Sciences et Avenir : L'Everest Guillaume Langin, Ciel & Espace : Où irons-nous vivre ? Elsa Couderc, The Conversation :Jusqu'où Einstein avait-il raison ?  François Lassagne, Pour la Science : Les nouveaux mondes de l'ARN.Musiques diffusées- Public Service Broadcasting – Everest- Beach House - Space Song- Goodie Mob, Outcast - Black Ice (Sky High)- I Monster – Cells- Piers Faccini, Ballaké Sissoko - If Nothing Is Real [Playlist RFI].

Prof Martin Hutchings from Copenhagen University Hospital in Denmark, Dr Manali Kamdar from the University of Colorado Cancer Center, Dr Matthew Lunning from the University of Nebraska Medical Center and Prof Gilles Salles from Memorial Sloan Kettering Cancer Center in New York summarize currently available data guiding treatment decision-making for patients with relapsed/refractory diffuse large B-cell lymphoma and present cases from their practices.CME information and select publications here.

Featuring slide presentations and related discussion from Prof Martin Hutchings, Dr Manali Kamdar, Dr Matthew Lunning and Prof Gilles Salles, including the following topics: Evolving Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (0:00) Case: A 61-year-old man with Stage IV non-GCB DLBCL receives R-CHOP but experiences disease progression 8 months later (30:39) Case: A 68-year-old man with double-hit DLBCL who experiences disease progression on chemotherapy and second-line CAR T-cell therapy receives glofitamab (39:22) Incorporation of Bispecific Antibody Therapy into DLBCL Management — Prof Hutchings (45:25) Case: A 42-year-old man with progressive DLBCL refractory to 2 lines of therapy receives glofitamab with a durable response (1:07:30) Case: An 81-year-old woman with multiregimen-refractory DLBCL experiences a prolonged response to epcoritamab (1:14:25) Case: A 69-year-old man with follicular lymphoma transformed to DLBCL and refractory to 3 lines of treatment receives glofitamab (1:21:48) Selection and Sequencing of Other Available Therapies for Relapsed/Refractory (R/R) DLBCL — Prof Salles (1:24:37) Case: An 82-year-old woman with follicular lymphoma transformed to DLBCL receives tafasitamab/lenalidomide (1:42:05) Case: A 69-year-old man with urinary bladder carcinoma and recurrent GCB DLBCL receives loncastuximab tesirine (1:46:26) Promising Investigational Approaches for Patients with R/R DLBCL — Dr Lunning (2:00:37) Case: An 80-year-old woman with multiregimen-refractory GCB DLBCL seeks treatment requiring minimal clinic visits and receives loncastuximab tesirine (2:15:59) Case: A 54-year-old man with primary refractory non-GCB DLBCL receives CAR T-cell therapy, and follow-up imaging on day 29 demonstrates a Deauville score of 4 (2:25:22) CME information and select publications

Prof Martin Hutchings from Copenhagen University Hospital in Denmark, Dr Manali Kamdar from the University of Colorado Cancer Center, Dr Matthew Lunning from the University of Nebraska Medical Center and Prof Gilles Salles from Memorial Sloan Kettering Cancer Center in New York summarize currently available data guiding treatment decision-making for patients with relapsed/refractory diffuse large B-cell lymphoma and present cases from their practices.CME information and select publications here.

The world is chaotic. Systems are failing, towns are burning. If you need to make an appointment with your doctor you may have to wait til July. So it's time to make a show about it all. I implore you to record moments of your day and send me the audio and I will try to make a show that sounds like RIGHT NOW. Email the recordings to me at rumblestripvermont@gmail.com.